Evidence map›Paper›PMID 31201628›Full record

ArticleDoklady. Biochemistry and biophysics2019

Loading Rate of Exogenous and Autoantigenic Determinants on Major Histocompatibility Complex Class II Mediates Resistance to Multiple Sclerosis.

A E Mamedov, M Yu Zakharova, O O Favorova, O G Kulakova, A N Boyko, V D Knorre, N A Vorobieva, E N Khurs, I S Kiselev, N M Baulina and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

A E MamedovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia. bioaz12@gmail.com.
M Yu ZakharovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia.
O O FavorovaPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, 117997, Moscow, Russia.
O G KulakovaPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, 117997, Moscow, Russia.
A N BoykoPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, 117997, Moscow, Russia.
V D KnorreShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia. vera.knorre@gmail.com.
N A VorobievaInstitute of Gene Biology, Russian Academy of Sciences, 119334, Moscow, Russia.
E N KhursEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
I S KiselevPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, 117997, Moscow, Russia.
N M BaulinaPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, 117997, Moscow, Russia.
A G GabibovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia.
A A BelogurovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia.
Pirogov Russian National Research Medical University · RUInstitute of Bioorganic Chemistry · RULomonosov Moscow State University · RUEngelhardt Institute of Molecular Biology · RUInstitute of Gene Biology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic analysis of thousands of patients with multiple sclerosis (MS) and healthy Russian donors showed that the carriage of groups of HLA-DRB1*15 and HLA-DRB1*03 alleles is associated with the risk of MS, whereas the carriage of groups of HLA-DRB1*01 and HLA-DRB1*11 alleles is protective. Recombinant HLA-DRB1*01:01 with a high affinity can recognize the fragments of myelin basic protein (MBP), one of the autoantigens in MS. However, the comparison of the kinetic parameters of the load of MBP and viral HA peptides on HLA-DRB1*01:01, which is catalyzed by HLA-DM, showed a significantly lower rate of exchange of CLIP for MBP peptides. We assume that the observed protective properties of the group of HLA-DRB1*01 alleles may be directly associated with the ability of HLA-DRB1*01:01 to kinetically distinguish peptides of exogenous and endogenous nature.

Indexed as

AutoantigensFemaleHLA-DRB1 ChainsHumansMaleMiddle AgedMultiple SclerosisMyelin Basic ProteinPeptidesAutoantigensHLA-DRB1 ChainsMBP protein, humanMyelin Basic ProteinPeptides

Identifiers

PMID31201628
OpenAlexW2947384598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.